Press Releases
Press Releases
Merck Receives Approval to Market GARDASIL®, ZOLINZA® and CUBICIN® in Japan
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved three products - GARDASIL® , ZOLINZA® (vorinostat) and CUBICIN® (daptomycin for injection) – for...
Press Releases
CiToxLAB appoints Paul C. Barrow as director of scientific projects and client consulting
CiToxLAB, a leading CRO in the field of non-clinical research, announces today that Paul C. Barrow has joined the company after serving ten years as a director of toxicology at Ricerca Biosciences. Barrow has more than...
Press Releases
Alkermes Announces Positive Results from Clinical Study of ALKS 9070 For Treatment of Schizophrenia
Alkermes, Inc. (NASDAQ: ALKS) today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia. ALKS 9070, a proprietary Alkermes molecule for the treatment of...
Press Releases
Provence Technologies and NexGenix announce successful lead compound development
Provence Technologies, a service provider in fine organic chemistry, and NexGenix Pharmaceuticals, a discovery and development company focused on the "next generation" of targeted therapies for cancer and diseases of the nervous system, announce today a successful collaboration for...
Press Releases
Adocia launches Phase IIa clinical study on type 1 diabetic patients with its fast-acting human insulin, HinsBet(R)
Adocia SAS, a privately-held biotechnology company specialized in regenerative medicine and in the treatment of chronic diseases, announced today the launch of its second clinical trial for the development of HinsBet(R), its fast-acting human insulin. ...
Press Releases
PupPharma moves into the Biocitech science park
Biocitech, the Paris life sciences technology park, announces the arrival of a new resident, PupPharma, which becomes the 27th company to set up shop there. PupPharma moved into the park in May, bringing a further expansion of the range...
Press Releases
Exclusive NHS Free podcast; Value Based Pricing: Do you get it?
Omar Ali is the Formulary Development Pharmacist for Surrey & Sussex Healthcare NHS Trust and also sits on the External reference Group for Cost Impact Modelling for NICE. eyeforpahrma have been working closely with Omar...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read